Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia

British Journal of Haematology

Volumn 144, Issue 6, 2009, Pages 930-932

  Gaikwad, Amos ^a   Rye, Cassia L ^b   Devidas, Meenakshi ^c   Heerema, Nyla A ^d   Carroll, Andrew J ^e   Izraeli, Shai ^f,g   Plon, Sharon E ^a   Basso, Giuseppe ^h   Pession, Andrea ⁱ   Rabin, Karen R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f Safra Children's Hospital   (Israel)

^g TEL AVIV UNIVERSITY   (Israel)

^h UNIVERSITY HOSPITAL OF PADOVA   (Italy)

ⁱ UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Acute lymphoblastic leukaemia; Down syndrome; JAK2; Paediatric

Indexed keywords

JANUS KINASE 2;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DIPLOIDY; DOWN SYNDROME; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; POINT MUTATION; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL;

AGE FACTORS; CHILD; CHILD, PRESCHOOL; DIPLOIDY; DISEASE-FREE SURVIVAL; DOWN SYNDROME; ENZYME ACTIVATION; HUMANS; JANUS KINASE 2; KAPLAN-MEIER ESTIMATE; MALE; POINT MUTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SEQUENCE ANALYSIS, DNA; SEX FACTORS;

EID: 60649110931     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07552.x     Document Type: Article

References (6)

1. Bercovich, D., Ganmore, I., Scott, L.M., Wainreb, G., Birger, Y., Elimelech, A., Shochat, C., Cazzaniga, G., Biondi, A., Basso, G., Cario, G., Schrappe, M., Stanulla, M., Strehl, S., Haas, O.A., Mann, G., Binder, V., Borkhardt, A., Kempski, H., Trka, J., Bielorei, B., Avigad, S., Stark, B., Smith, O., Dastugue, N., Bourquin, J.P., Tal, N.B., Green, A.R. Izraeli, S. (2008) Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet, 372, 1484 1492.
2. Hasle, H., Clemmensen, I.H. Mikkelsen, M. (2000) Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet, 355, 165 169.
3. Kearney, L., Gonzalez De, C.D., Yeung, J., Procter, J., Horsley, S.W., Eguchi-Ishimae, M., Bateman, C.M., Anderson, K., Chaplin, T., Young, B.D., Harrison, C.J., Kempski, H., So, C.W., Ford, A.M. Greaves, M. (2008) A specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukaemia. Blood, Prepublished online October 16, 2008; doi :.
4. Malinge, S., Ben-Abdelali, R., Settegrana, C., Radford-Weiss, I., Debre, M., Beldjord, K., Macintyre, E.A., Villeval, J.L., Vainchenker, W., Berger, R., Bernard, O.A., Delabesse, E. Penard-Lacronique, V. (2007) Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood, 109, 2202 2204.
5. Peto, R., Pike, M.C., Armitage, P., Breslow, N.E., Cox, D.R., Howard, S.V., Mantel, N., McPherson, K., Peto, J. Smith, P.G. (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. British Journal of Cancer, 35, 1 39.
6. Wechsler, J., Greene, M., McDevitt, M.A., Anastasi, J., Karp, J.E., Le Beau, M.M. Crispino, J.D. (2002) Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nature Genetics, 32, 148 152.